ID: MRFR/Pharma/2690-HCR | February 2021 | Region: Global | 90 pages
Synopsis of Agoraphobia Market:
Considering all these factors, the market for agoraphobia diagnosis and treatment is expected to reach $ 800 million by the end of 2023, this market is projected to growing at a CAGR of ~ 4.3 % during 2017-2023.
Figure 1 Global Agoraphobia market by Surgery, 2016 (% Market Share)
Agoraphobia Market Segments:
The global agoraphobia market is segmented on the basis of drug treatment, therapy and end users. Based on drug treatment, the agoraphobia market has been segmented as selective serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, tricyclic antidepressants, anti-anxiety medications and others. Based on the therapy, the market has been segmented as psychotherapy, cognitive behavioral therapy (CBT), exposure therapy and others. Based on the end users, the market has been segmented as hospitals, clinics, academics and others.
Agoraphobia Market Regional Analysis
US accounts for the maximum market share due to favorable insurance penetration, excellent reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global agoraphobia diagnosis and treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region agoraphobia market is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Key players of Global Agoraphobia market:
Key players profiled in the agoraphobia market report are Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, Pfizer inc, GlaxoSmithKline plc, Johnson & Johnson, Sandoz Inc., Apotex Corp., Mylan Pharmaceuticals Inc. and others.
The report for Global agoraphobia market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different agoraphobia market segments and regions.
Sources: Mayo Clinic, MRFR Analysis.
|Market Size||2023: USD 800 million|
|CAGR||2017-2023: ~ 4.3%|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug treatment, Therapy and End users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Eli Lilly & Co., Bristol-Myers Squibb, AstraZeneca, Pfizer inc, GlaxoSmithKline plc, Johnson & Johnson, Sandoz Inc., Apotex Corp., Mylan Pharmaceuticals Inc|
|Key Market Opportunities||
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
agoraphobia market is touted to touch USD 800 million by 2023.
agoraphobia market is expected to register 4.3% from 2017 to 2023.
The U.S. has the largest market share in the global agoraphobia market due to insurance schemes and favorable reimbursement schemes.
The APAC region has the largest potential in the global agoraphobia market.
Eli Lilly & Co., AstraZeneca, Bristol-Myers Squibb, Apotex Corp., Johnson & Johnson, Pfizer Inc, Sandoz Inc., Mylan Pharmaceuticals Inc., and GlaxoSmithKline plc are major players of the global agoraphobia market.